The Antimicrobial Activity of a Carbon Monoxide Releasing Molecule (EBOR-CORM-1) Is Shaped by Intraspecific Variation within Pseudomonas aeruginosa Populations.

Frontiers in Microbiology
Lindsey FlanaganVille-Petri Friman

Abstract

Carbon monoxide releasing molecules (CORMs) have been suggested as a new synthetic class of antimicrobials to treat bacterial infections. Here we utilized a novel EBOR-CORM-1 ([NEt4][MnBr2(CO)4]) capable of water-triggered CO-release, and tested its efficacy against a collection of clinical Pseudomonas aeruginosa strains that differ in infection-related virulence traits. We found that while EBOR-CORM-1 was effective in clearing planktonic and biofilm cells of P. aeruginosa strain PAO1 in a concentration dependent manner, this effect was less clear and varied considerably between different P. aeruginosa cystic fibrosis (CF) lung isolates. While a reduction in cell growth was observed after 8 h of CORM application, either no effect or even a slight increase in cell densities and the amount of biofilm was observed after 24 h. This variation could be partly explained by differences in bacterial virulence traits: while CF isolates showed attenuated in vivo virulence and growth compared to strain PAO1, they formed much more biofilm, which could have potentially protected them from the CORM. Even though no clear therapeutic benefits against a subset of isolates was observed in an in vivo wax moth acute infection model, EBOR-CORM-1 was...Continue Reading

References

Mar 29, 2000·Journal of Applied Microbiology·W L CochranP S Stewart
Jul 21, 2001·Lancet·P S Stewart, J W Costerton
Aug 23, 2002·Journal of Internal Medicine·B Henriques Normark, S Normark
May 12, 2004·Free Radical Biology & Medicine·Krzysztof J ReszkaBradley E Britigan
Nov 26, 2004·Journal of the American Chemical Society·Shen LuPierre Moënne-Loccoz
May 12, 2006·Proceedings of the National Academy of Sciences of the United States of America·Eric E SmithMaynard V Olson
Jun 21, 2007·American Journal of Clinical Pathology·Bobbi PrittWashington Winn
Oct 10, 2007·Antimicrobial Agents and Chemotherapy·Lígia S NobreLígia M Saraiva
Jan 9, 2008·The ISME Journal·Freya HarrisonAngus Buckling
May 1, 1994·Biotechnology and Bioengineering·D de BeerZ Lewandowski
Jan 20, 1997·Biotechnology and Bioengineering·D de BeerZ Lewandowski
Dec 20, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mathieu DesmardJorge Boczkowski
Aug 8, 2009·Dalton Transactions : an International Journal of Inorganic Chemistry·Wei-Qiang ZhangJason M Lynam
Aug 3, 2010·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Cystic Fibrosis Foundation Pulmonary Therapies Committee
Sep 3, 2010·Nature Reviews. Drug Discovery·Roberto Motterlini, Leo E Otterbein
Feb 8, 2011·American Journal of Respiratory and Critical Care Medicine·Eilidh MowatCraig Winstanley
Jul 13, 2011·Frontiers in Microbiology·Keith Poole
Dec 6, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Susan M van DommelenRaymond M Schiffelers
Jun 1, 2012·Proceedings. Biological Sciences·Kendra P RumbaughStuart A West
Nov 14, 2012·Nature Reviews. Microbiology·Anders FolkessonSøren Molin
Mar 5, 2013·Nature Reviews. Microbiology·Daniel M Cornforth, Kevin R Foster
Apr 11, 2013·PloS One·Matthew L WorkentineMichael G Surette
Jul 1, 2014·The Journal of Physical Chemistry. a·Moritz KleinJürgen Popp
Jan 16, 2015·American Journal of Respiratory and Critical Care Medicine·David WilliamsSteve Paterson
Jun 10, 2015·The Journal of Biological Chemistry·Lauren K WarehamMariana Tinajero-Trejo
Aug 28, 2015·Proceedings. Biological Sciences·Melanie GhoulAshleigh S Griffin
Jan 15, 2016·Biology Letters·T KetolaJ Mappes
Jan 23, 2016·Nature·Eric D Brown, Gerard D Wright
Mar 8, 2016·Trends in Microbiology·Craig WinstanleyMichael A Brockhurst
Jul 16, 2016·Dalton Transactions : an International Journal of Inorganic Chemistry·Jorge JimenezPradip K Mascharak
Aug 16, 2016·Microbiology·Freya Harrison, Stephen P Diggle

❮ Previous
Next ❯

Citations

Aug 31, 2018·Bioinorganic Chemistry and Applications·Aiten IsmailovaIan S Butler
Sep 29, 2020·Frontiers in Bioengineering and Biotechnology·Wen Kang ChouMark P Brynildsen
Oct 11, 2019·Dalton Transactions : an International Journal of Inorganic Chemistry·Jonathan S WardIan J S Fairlamb
Jun 3, 2021·Antioxidants·Sofia S MendesLígia M Saraiva

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

CytExpert
CORM
EBOR

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.